Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Relypsa's patiromer gains FDA approval of sNDA, black box warning removed from label

Nov. 29, 2016

Inisync available in Japan

Nov. 29, 2016

Oxford BioMedica establishes strategic alliance with Orchard Therapeutics

Nov. 29, 2016

European Commission approves Glyxambi for type 2 diabetes

Nov. 29, 2016

Zinc-13407541 partially reverses hypophosphatemic effects of excess FGF-23 in vivo

Nov. 29, 2016

Araim Pharmaceuticals' ARA-290 granted orphan drug designation in E.U.

Nov. 28, 2016

FN1 is significantly upregulated in ASM vs. ISM

Nov. 25, 2016

First patient given allogeneic adipose tissue-derived multilineage progenitor cells in phase I study

Nov. 25, 2016

PRX-OTC from PhaseRx receives FDA orphan drug designation

Nov. 24, 2016

Novo Nordisk's Xultophy wins FDA approval for type 2 diabetes

Nov. 22, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 8, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...